To further investigate the duration of the effects of C3G on GLP-1 and insulin release, we conducted time course experiments utilizing the optimal concentration of C3G
3), comparisons are limited due to differences in endpoint definitions across studies: nevertheless, CVOTs results suggest substantial kidney protection with both monotherapy and combination therapy, except for the FLOW trial
Evidence of (positive or inverse) associations with other histological types was not observed
NEJM 2025 (REDEFINE-2) Novo Nordisk FDA NDA submission announcement (December 18, 2025) Eli Lilly TRIUMPH-4 topline results (December 2025) Frequently Asked Questions Retatrutide produces higher weight loss at 28.7% versus CagriSema's 20.4%a difference of 21 pounds for a 250-pound person
For market researchers, investors, pharma strategists, and healthcare companies, the opportunity is clear